- Home
- MGIC vs ELVN Comparison
MGIC vs ELVN Comparison
Compare MGIC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGIC | ELVN |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 1.1B |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MGIC | ELVN |
|---|---|---|
| Price | $25.91 | $17.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $18.00 | ★ $41.20 |
| AVG Volume (30 Days) | 45.8K | ★ 767.6K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $603,216,000.00 | N/A |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $30.35 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.36 | $13.30 |
| 52 Week High | $27.44 | $25.37 |
Technical Indicators
Market Signals| Indicator | MGIC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 36.75 |
| Support Level | $24.52 | $15.71 |
| Resistance Level | $27.44 | $17.58 |
| Average True Range (ATR) | 0.83 | 1.36 |
| MACD | -0.05 | -0.43 |
| Stochastic Oscillator | 65.20 | 17.77 |
Price Performance
Historical ComparisonAbout MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.